The global post-traumatic stress disorder (PTSD) treatment market is expected to garner market value of US$ 16.8 billion in 2023 and is expected to accumulate a market value of US$ 27.37 billion by registering a CAGR of 5% in the forecast period 2023 to 2033. Growth of the post-traumatic stress disorder (PTSD) treatment market can be attributed to the innovation of therapies along with growing prevalence of the ailment. The market for post-traumatic stress disorder (PTSD) treatment registered a CAGR of 3.3% in the historical period 2018 to 2022
Post-Traumatic Stress Disorder (PTSD) treatment is a type of therapy that is used to help people who have experienced a traumatic event and are struggling with the aftermath. PTSD is a mental health condition that can occur after a person experiences or witnesses a traumatic event such as a natural disaster, combat, sexual assault, or a serious accident.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | US$ 16.8 billion |
| Anticipated Forecast Value (2033) | US$ 27.37 billion |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for post-traumatic stress disorder (PTSD) treatment reflected a value of 3.3% during the historical period, 2018 to 2022. Several factors have contributed to this growth, including increasing awareness of PTSD and mental health issues, growing demand for mental health services, and the development of new and innovative treatments for PTSD.
In recent years, there has been a significant focus on the development of new treatments for PTSD, including non-pharmacological therapies such as psychotherapy and virtual reality therapy. The growing adoption of these therapies, along with the increasing availability of pharmacological treatments, is driving the growth of the PTSD treatment market. Thus, the market for post-traumatic stress disorder (PTSD) treatment is expected to register a CAGR of 5% in the forecast period 2023 to 2033.
Growing awareness about mental health contributing to market growth of PTSD treatment
The rising incidence of PTSD due to traumatic events such as natural disasters, terrorist attacks, and armed conflicts is a major driver of the PTSD treatment market. According to the National Institute of Mental Health, an estimated 7.7 million adults in the United States have PTSD.
The growing awareness about mental health and the importance of seeking treatment for mental health conditions is driving the demand for PTSD treatment. People are becoming more aware of the importance of seeking help and support for mental health issues, including PTSD. The development of new and innovative therapies and technologies for the treatment of PTSD, such as virtual reality therapy, is driving the growth of the PTSD treatment market. These new therapies offer alternative treatment options for people with PTSD.
The growing demand for personalized medicine and targeted therapies is driving the development of new PTSD treatments that are tailored to the individual needs of patients. Governments around the world are increasing their support for mental health programs and initiatives, which is driving the growth of the PTSD treatment market. Governments are investing in mental health research and treatment programs to improve the quality of life for people with PTSD.
Availability of treatment and therapies favoring growth of the PTSD market growth
Psychotherapy: Psychotherapy is a type of talk therapy that is used to help people with PTSD. There are several types of psychotherapy that can be used to treat PTSD, including cognitive behavioral therapy (CBT), prolonged exposure therapy, and eye movement desensitization and reprocessing (EMDR).
Medication: Medication can be used to help manage symptoms of PTSD such as depression, anxiety, and insomnia. Common medications used to treat PTSD include antidepressants, anti-anxiety medications, and sleep aids.
Self-help strategies: There are several self-help strategies that can be used to manage symptoms of PTSD, such as exercise, relaxation techniques, and mindfulness meditation.
Support groups: Support groups can provide a sense of community and understanding for people with PTSD. Group therapy can also be helpful in providing a safe and supportive environment for people to share their experiences and learn coping strategies.
Principal Consultant
Stigma associated with mental illness and limited access to mental health services
There is still a stigma associated with mental illness, including PTSD, which can prevent people from seeking help and accessing treatment. Many people with PTSD face barriers to accessing mental health services, including limited availability of mental health professionals, lack of insurance coverage, and long wait times for appointments.
PTSD is a complex condition that is not fully understood, which can make it challenging to develop effective treatments. There is still much to learn about the underlying causes and mechanisms of PTSD. There is no consensus on the best approach to treating PTSD, and different therapies and treatments may be more effective for different people. This can make it challenging to develop standardized treatment guidelines.
The cost of PTSD treatment can be high, particularly for individuals who do not have insurance coverage or access to affordable mental health services. This can be a barrier to accessing treatment for many people. Adherence to treatment can be a challenge for people with PTSD, particularly given the complexity of the condition and the long-term nature of treatment. Many people with PTSD may struggle to stick to a treatment plan, which can impact the effectiveness of treatment.
Growing awareness of the importance of mental health bolstering demand for treatments for PTSD
North America is a significant market for Post-Traumatic Stress Disorder (PTSD) treatment, driven by the high prevalence of PTSD in the region and the growing demand for mental health services. The United States and Canada are the major contributors to the PTSD treatment market in North America.
In the United States, PTSD affects an estimated 8 million adults every year, and the condition is more prevalent among veterans, first responders, and survivors of sexual assault or domestic violence. The growing awareness of the importance of mental health, increased government funding for mental health programs, and a rise in the number of mental health professionals are some of the factors driving the growth of the PTSD treatment market in the United States.
Canada is also a significant market for PTSD treatment, with an estimated 10% of Canadians experiencing PTSD at some point in their lives. The Canadian government has made mental health a priority, and there has been an increase in funding for mental health programs and services. The growing demand for mental health services and the availability of innovative therapies such as virtual reality therapy are driving the growth of the PTSD treatment market in Canada.
Overall, the North America PTSD treatment market is expected to grow due to the high prevalence of PTSD, growing awareness of mental health issues, increasing government support, and the availability of innovative therapies. Thus, the North America is expected to possess a 43% market share for PTSD market in 2023.
Availability of innovative therapies shaping landscape for PTSD market in Europe
Europe is a significant market for Post-Traumatic Stress Disorder (PTSD) treatment, driven by the high prevalence of PTSD in the region and the increasing demand for mental health services. The major contributors to the PTSD treatment market in Europe are the United Kingdom, Germany, France, Italy, and Spain.
In the United Kingdom, PTSD affects an estimated 4% of the population, with higher rates among military personnel and emergency responders. The growing awareness of the importance of mental health, increasing government funding for mental health programs, and the availability of innovative therapies such as Eye Movement Desensitization and Reprocessing (EMDR) are some of the factors driving the growth of the PTSD treatment market in the United Kingdom.
Germany is also a significant market for PTSD treatment, with an estimated 5% of the population experiencing PTSD at some point in their lives. The German government has made mental health a priority, and there has been an increase in funding for mental health programs and services. The growing demand for mental health services and the availability of innovative therapies such as cognitive-behavioral therapy (CBT) and exposure therapy are driving the growth of the PTSD treatment market in Germany. Thus, Europe is expected to possess a 42% market share for PTSD market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Efficiency of antidepressants commercializing the use of same for PTSD treatment
Antidepressants are often prescribed for PTSD because they can help alleviate symptoms such as depression, anxiety, and sleep disturbances. They work by regulating levels of certain neurotransmitters in the brain, such as serotonin and norepinephrine, which can be imbalanced in people with PTSD. Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed type of antidepressants for PTSD.
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants for PTSD. They work by increasing the levels of serotonin in the brain, which can improve mood, reduce anxiety and improve sleep patterns. Some commonly prescribed SSRIs for PTSD include fluoxetine, paroxetine, and sertraline.
Other types of antidepressants, such as serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs) may also be used in some cases. Thus, antidepressants are expected to possess a 41% market share for PTSD market in 2023.
Key players in the post-traumatic stress disorder (PTSD) treatment market are Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceutical Development & Commercialization, Inc., Bionomics Limited, Merck KGaA, Pfizer Inc., Aurobindo Pharma Limited, GlaxoSmithKline plc, Viatris Inc., Jubilant Pharmova
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 16.8 billion |
| Market Value in 2033 | US$ 27.37 billion |
| Growth Rate | CAGR of 5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The post-traumatic stress disorder (PTSD) treatment market is valued at US$ 16.8 billion in 2023.
Until 2033, the market is likely to experience a 5% CAGR.
The market is expected to reach US$ 27.37 billion in 2033.
From 2018 to 2022, the market registered a CAGR of 3.3%.
GlaxoSmithKline plc, Viatris Inc., and Jubilant Pharmova are the leading companies in the market.
1. Executive Summary | Post-Traumatic Stress Disorder (PTSD) Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Antidepressants
5.3.2. Anti-anxiety Drugs
5.3.3. Antipsychotics
5.3.4. Other Drug Classes
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Drug Class
8.2.3. By Distribution Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Drug Class
8.3.3. By Distribution Channel
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Drug Class
9.2.3. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Distribution Channel
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. United kingdom
10.2.1.2. Spain
10.2.1.3. Germany
10.2.1.4. Italy
10.2.1.5. France
10.2.1.6. Rest of Europe
10.2.2. By Drug Class
10.2.3. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Distribution Channel
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. India
11.2.1.4. South Korea
11.2.1.5. Rest of Asia Pacific
11.2.2. By Drug Class
11.2.3. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Distribution Channel
11.4. Key Takeaways
12. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. South Africa
12.2.1.2. GCC Countries
12.2.1.3. Rest of Middle East and Africa
12.2.2. By Drug Class
12.2.3. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Distribution Channel
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. USA
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Drug Class
13.1.2.2. By Distribution Channel
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Drug Class
13.2.2.2. By Distribution Channel
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Drug Class
13.3.2.2. By Distribution Channel
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Drug Class
13.4.2.2. By Distribution Channel
13.5. United kingdom
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Drug Class
13.5.2.2. By Distribution Channel
13.6. Spain
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Drug Class
13.6.2.2. By Distribution Channel
13.7. Germany
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Drug Class
13.7.2.2. By Distribution Channel
13.8. Italy
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Drug Class
13.8.2.2. By Distribution Channel
13.9. France
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Drug Class
13.9.2.2. By Distribution Channel
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Drug Class
13.10.2.2. By Distribution Channel
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Drug Class
13.11.2.2. By Distribution Channel
13.12. India
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Drug Class
13.12.2.2. By Distribution Channel
13.13. South Korea
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Drug Class
13.13.2.2. By Distribution Channel
13.14. South Africa
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Drug Class
13.14.2.2. By Distribution Channel
13.15. GCC Countries
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Drug Class
13.15.2.2. By Distribution Channel
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Drug Class
14.3.3. By Distribution Channel
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Jazz Pharmaceuticals
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Aptinyx
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Otsuka Pharmaceutical Development & Commercialization, Inc.
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Bionomics Limited
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Merck KGaA
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Pfizer Inc.
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Aurobindo Pharma Limited
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. GlaxoSmithKline plc
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Viatris Inc.
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Jubilant Pharmova
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Explore Healthcare Insights
View Reports
Post-Traumatic Stress Disorder (PTSD) Treatment Market
